Toxicity and morbidity of isolated limb perfusion

Seminars in Surgical Oncology

Volumn 14, Issue 3, 1998, Pages 224-231

  Vrouenraets, Bart C ^a   Klaase, Joost M ^a   Nieweg, Omgo E ^a   Kroon, Bin B R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Combined modality therapy; Drug dose response relationship; Extremities; Induced hyperthermia; Lymph node dissection; Lymphedema; Melanoma; Melphalan administration and dosage adverse effects toxicity; Postoperative complications; Regional perfusion methods adverse effects contraindications; Risk factors; Sarcoma; Tumor necrosis factor

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

BLOOD FLOW VELOCITY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG MONITORING; FASCIOTOMY; HUMAN; JOINT STIFFNESS; LIMB PERFUSION; LYMPH NODE DISSECTION; LYMPHEDEMA; MELANOMA; MUSCLE ATROPHY; NEPHROTOXICITY; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SEX DIFFERENCE; THROMBOSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; MELANOMA; MELPHALAN; MORBIDITY; RISK FACTORS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031893170     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199804/05)14:3<224::AID-SSU6>3.0.CO;2-A     Document Type: Review

References (70)

1. Vrouenraets BC, Nieweg OE, Kroon BB: Thirty-five years of isolated limb perfusion for melanoma: indications and results [Review]. Br J Surg 1996;83:1319-1328.
2. Eggermont AM, Schraffordt Koops H, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcoma: the cumulative multicenter European experience. Ann Surg 1996;224:756-765.
3. Schraffordt Koops H, Kroon BB, Lejeune FJ: Management of local recurrence, satellites, and in transit metastases of the limbs with isolation perfusion. In Lejeune FJ, Chaudhuri PK, Das Gupta T (eds): "Malignant melanoma: medical and surgical management." New York: McGraw-Hill; 1994. p. 221-231.
4. Krementz ET, Carter RD, Sutherland CM, et al: Regional chemotherapy for melanoma. A 35-year experience. Ann Surg 1994; 220:520-535.
5. Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs [Review]. World J Surg 1992;16:227-233.
6. Wieberdink J, Benckhuysen C, Braat RP, et al: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.
7. Klaase JM, Kroon BB, van Geel AN, et al: Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994;167:618-620.
8. Thompson JF, Lai DT, Ingvar C, et al: Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994;4(Suppl 1):45-50.
9. Vrouenraets BC, Kroon BB, Klaase JM, et al: Severe acute regional toxicity after normothermic or "mild" hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995;5: 425-431.
10. Liénard D, Lejeune F, Autier P, et al: Physiological and pharmacokinetics parameters in isolation perfusion of the limbs. In Lejeune FJ, Chaudhuri PK, Das Gupta T (eds): "Malignant melanoma: medical and surgical management." New York: McGraw-Hill; 1994. p. 241-248.
11. Vrouenraets BC, Klaase JM, Eggermont AM, et al: No relation between limb toxicity and treatment outcome after isolated limb perfusion (ILP) for measurable melanoma [Abstract]. Melanoma Res 1997;7(Suppl 1):S111.
12. Vrouenraets BC, Klaase JM, Kroon BB, et al: Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995;130:43-47.
13. Klaase JM, Kroon BB, van Slooten GW, Benckhuijsen C: Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Res Cancer Treat 1992;4:309-312.
14. Thompson JF, Eksborg S, Kam PC, et al: Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res 1996;6:267-271.
15. Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J: Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157-163.
16. Thompson JF, Good PD, Kam PC: Hyperthermic isolated limb perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat 1994;1:147-154.
17. Kroon BB, Klaase JM, van Geel BN, Eggermont AM: Application of hyperthermia in regional isolated perfusion for melanoma of the limbs Reg Cancer Treat 1992;4:223-226.
18. Cavaliere R, Ciocatto EC, Giovanella BC, et al: Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer 1967;20:1351-1381.
19. Stehlin JS Jr: Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969;129:305-308.
20. Pace M, Galli A, Bellacci A: Local and systemic toxicity in "borderline true" hyperthermic isolated perfusion for lower limb melanoma. Melanoma Res 1995;5:371-376.
21. Cavaliere R, Cavaliere F, Deraco M, et al: Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two methods [published erratum in Melanoma Res 1994;4:269]. Melanoma Res 1994;4(Suppl 1):5-11.
22. Thompson JF, Kam PC, Razan D, Yau DF: Clinical pharmacokinetics of melphalan in isolated limb perfusion: compartmental modelling and moment analysis. Reg Cancer Treat 1994;8:83-87.
23. Klaase JM, Kroon BB, Eggermont AM, et al: A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995;31A:58-63.
24. Scott RN, Blackie R, Kerr DJ, et al: Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In Jakesz R, Rainer H (eds): "Progress in regional cancer therapy." Berlin-Heidelberg: Springer-Verlag; 1990. p. 195-200.
25. Wieberdink J: "Physiological considerations regarding isolation perfusion of the extremities." Meppel, the Netherlands: Krips Repro; 1978.
26. Vrouenraets BC, Kroon BB, van de Merwe SA, et al: Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: a pilot study. Eur Surg Res 1996;28:235-244.
27. Furner RL, Brown RK: L-phenylalanine mustard (L-PAM): the first 25 years [Review]. Cancer Treat Rep 1980;64:559-574.
28. 2 histogram) to the skeletal muscle. Surgery 1985;97:278-284.
29. Krementz ET, Saha S: Limb perfusion with melphalan for melanoma by increased dose and dilution compared to standard technique: a pilot study. Reg Cancer Treat 1989;2:233-237.
30. Klaase JM, Kroon BB, van Slooten GW, et al: Comparison between the use of whole blood versus a diluted perfusate in regional isolated perfusion by continuous monitoring of transcutaneous oxygen tension: a pilot study. J Invest Surg 1994;7:249-258.
31. Lai DT, Ingvar C, Thompson JF: The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1993;1:36-39.
32. Vrouenraets BC, Kroon BB, Klaase JM, et al: Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol 1997;4:88-94.
33. Rauschecker HF, Osterloh B: Acute renal failure following hyperthermic isolation perfusion of the left leg. Anticancer Res 1987;7(3 Pt B):451-454.
34. Schraffordt Koops H: Prevention of neural and muscular lesions during hyperthermic regional perfusion. Surg Gynecol Obstet 1972;135:401-403.
35. Hohenberger P, Finke LH, Schlag PM: Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma. Eur J Surg Oncol 1996;22:147-151.
36. Vrouenraets BC, Eggermom AM, Klaase JM, et al: Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 1994;20:681-685.
37. Klein ES, Walden R, Ben-Ari GY: Peripheral blood flow studies following isolated limb perfusion with cisplatin. Reg Cancer Treat 1993;3:137-139.
38. Muchmore JH, Krementz ET, Kerstein MD: Noninvasive evaluation of peripheral vasculature following regional hyperthermic chemotherapeutic perfusion (RHCP). Am Surg 1987;53:94-96.
39. Klicks RJ, Nieweg OE, Vrouenraets BC, Kroon BB: Vascular complications of regional isolation perfusion of the extremities [Abstract]. VII International Congress on Regional Cancer Treatment. Wiesbaden, Germany, September 11-13, 1995:69.
40. Rosin DR: Isolated limb perfusion: past experience and present studies using a minimal-access approach. Melanoma Res 1994;4(Suppl 1):51-55.
41. Schraffordt Koops H, Oldhoff J, Oosterhuis JW: Commentary on isolated limb perfusion performed at the University of Groningen, The Netherlands. In Balch CH, Milton GW (eds). "Cutaneous melanoma: clinical management and treatment worldwide." Philadelphia: Lippincott; 1985. p. 191-193.
42. Klaase JM, Kroon BB, van Geel AN, et al: A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993;71:2990-2994.
43. Klop WM, Vrouenraets BC, van Geel AN, et al: Repeat isolated limb perfusion with melphalan for recurrent melanoma. J Am Coll Surg 1996;82:467-472.
44. Krementz ET, Ryan RF, Carter RD, et al: Hyperthermic regional perfusion of the limbs. In Balch CH, Milton GW (eds): "Cutaneous melanoma: clinical management and treatment worldwide." Philadelphia: Lippincott; 1985. p. 171-190.
45. Lejeune FJ, Deloof T, Ewalenko P, et al: Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Res Cancer Res 1983;86:268-276.
46. Baas PC, Schraffordt Koops H, Hoekstra HJ, et al: Groin dissection in the treatment of lower-extremity melanoma: short-term and long-term morbidity. Arch Surg 1992;127:281-286.
47. Bulman AS, Jamieson CW: Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg 1980;67:660-662.
48. Stehlin JS Jr, Clark RL: Melanoma of the extremities: experience with conventional treatment and perfusion in 339 cases. Am J Surg 1965;110:366-383.
49. Olieman AF, Schraffordt Koops H, Geertzen JH, et al: Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1994;1:382-388.
50. van Geel AN, van Wijk J, Wieberdink J: Functional morbidity after regional isolated perfusion of the limbs for melanoma. Cancer 1989;63:1092-1096.
51. Briele HA, Djuric M, Jung DT, et al: Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 1985;45:1885-1889.
52. Scon RN, Kerr DJ, Blackie R, et al: The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 1992;66:159-166.
53. Hoekstra HJ, Naujocks T, Schraffordt Koops H, et al: Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. Reg Cancer Treat 1992;4:301-304.
54. Neades GT, Evans WD, Mansel RE: Choice of agent and prediction of systemic toxicity in isolated hyperthermic limb perfusion. Reg Cancer Treat 1991;3:252-255.
55. Klaase JM, Kroon BB, van Geel AN, et al: Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993;80:1124-1126.
56. Sonneveld FJ, Vrouenraets BC, van Geel BN, et al: Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 1996;22:521-527.
57. Thompson JF, Malouf DJ, Merzliakov S, Kam PC: Efficacy of single-dose ondansetron in the prevention of post-operative nausea and vomiting following isolated limb perfusion with cytostatic agents. Reg Cancer Treat 1993;4:177-182.
58. Liénard D, Lejeune F, Ewalenko P: In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-γ and melphalan in isolation perfusion. World J Surg 1992;16:234-240.
59. Fraker DL, Alexander HR: Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. Important Adv Oncol 1994. 1994:179-192.
60. Yang JC, Fraker DL, Thom AK, et al: Isolation perfusion with tumor necrosis factor-α, interferon-γ, and hyperthermia in the treatment of localized and metastatic cancer [Review]. Recent Res Cancer Res 1995;138:161-166.
61. Gérain J, Liénard D, Ewalenko P, Lejeune FJ: High serum levels of TNFα after its administration for isolation perfusion of the limbs. Cytokine 1992;4:585-591.
62. Vaglini M, Belli F, Ammatuna M, et al: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994;73:483-192.
63. Thom AK, Alexander HR, Andrich MP, et al: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995;13:264-273.
64. Swaak AJ, Liénard D, Schraffordt Koops H, et al: Effects of recombinant tumor necrosis factor alpha (rTNFα) in cancer. Observations of the acute phase protein reaction and immunoglobin synthesis after high dose rTNF-α administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 1993;23:812-818.
65. Vrouenraets BC, Kroon BB, Ogilvie AC, et al: Absence of severe systemic toxicity after leakage controlled isolated limb perfusion with high-dose TNFα + melphalan [Abstract]. Melanoma Res 1997;7(Suppl 1):S111.
66. Coit DG: Isolation limb perfusion for melanoma: current trends and future direction [Review]. Melanoma Res 1994;4(Suppl 1):57-60.
67. Busse O, Aigner K, Wilimzig H: Peripheral nerve damage following isolated extremity perfusion with cis-platinum. Recent Cancer Res 1983;86:264-267.
68. Guchelaar HJ, Hoekstra HJ, de Vries EG, et al: Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumors of the extremities. Br J Cancer 1992;65:898-902.
69. Klaase JM, Kroon BB, Benckhuijsen C, et al: Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616-621.
70. Rossi CR, Vecchiato A, Foletto M, et al: Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140-2146.